Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Papilloguard 4
- Development stage
- Unknown
- Lead developer
- NIVAD Pharmed Salamat
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**Papilloguard 4** is a quadrivalent recombinant virus-like particle (VLP) vaccine developed by **Nivad Pharmed Salamat** (a spin-off of **Noyan Pajouhan Biopharma**). It is designed to protect against infection and related diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18. The vaccine contains recombinant major capsid L1 proteins of these four HPV genotypes, which self-assemble into non-infectious VLPs that mimic the native virus structure to elicit a robust neutralizing antibody response. Unlike the reference quadrivalent vaccine Gardasil, which uses an aluminum-based adjuvant, Papilloguard 4 is formulated with the **AS04** adjuvant system (monophosphoryl lipid A adsorbed on aluminum hydroxide) to enhance immunogenicity. It is currently in Phase III clinical development in Iran for the prevention of HPV infection, genital warts, and HPV-related cancers such as cervical cancer.
- Brand names
- Papilloguard 4Papilloguard4Papilloguard-4
- Other names
- quadrivalent Papilloguardquadrivalent Papilloguard 4
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Papilloguard 4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Papilloguard 4.